newsfilter
← Latest News
Business Wire·

ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results

Continued Strong Momentum with ELAHERE Launch in US; Net Sales of $77.4 Million in Q2 Presented Positive Results for ELAHERE from Phase 3 MIRASOL Trial During Late-Breaking Oral Presentation at ASCO; First Therapy to